 CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 GLOBE NEWSWIRE -- CENTOGENE Nasdaq: CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the nomination of Dr. Jonathan G. Sheldon as a member of the Supervisory Board, which will be proposed to the shareholders at an upcoming Extraordinary General Meeting EGM. Dr. Sheldon will also serve with immediate effect as a member ad interim of the Companys Supervisory Board. 